Page last updated: 2024-08-22

camptothecin and gsk 2126458

camptothecin has been researched along with gsk 2126458 in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Chen, Y; Han, J; Liu, T; Song, Y; Wang, M; Xu, H; Yang, C; Zhang, L; Zheng, C; Zhu, J	1

Other Studies

1 other study(ies) available for camptothecin and gsk 2126458

Article	Year
Structure-based optimization leads to the discovery of NSC765844, a highly potent, less toxic and orally efficacious dual PI3K/mTOR inhibitor. European journal of medicinal chemistry, 2016, Oct-21, Volume: 122 Topics: Administration, Oral; Amino Acid Sequence; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Design; Enzyme Inhibitors; Humans; Male; Models, Molecular; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Conformation; Rats; Signal Transduction; Structure-Activity Relationship; Sulfonamides; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays	2016

Article

Year

Structure-based optimization leads to the discovery of NSC765844, a highly potent, less toxic and orally efficacious dual PI3K/mTOR inhibitor.

European journal of medicinal chemistry, 2016, Oct-21, Volume: 122

Topics: Administration, Oral; Amino Acid Sequence; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Design; Enzyme Inhibitors; Humans; Male; Models, Molecular; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Conformation; Rats; Signal Transduction; Structure-Activity Relationship; Sulfonamides; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays

2016